Talazoparib-Enzalutamide Improves Survival in Metastatic CRPC

(MedPage Today) -- SAN FRANCISCO -- Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate cancer (CRPC) prolonged survival, new analyses from the TALAPRO-2 trial indicated.
In...